Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 23%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is a promising company with a strong pipeline of innovative oncology drugs and a successful and in-demand covid vaccine. Financially, the company is projected to have a firm value of $33B and has potential for future partnerships and market uptake. While risks do exist, BioNTech's advancements in the field of immunotherapy and its positive clinical trial data make it a strong investment opportunity with a potential upside reflected in the price target of $130 per share.

Bears say

BioNTech is facing several key risks, including: (1) competition from other biotech companies with similar products or pipelines; (2) potential failure of their cancer therapeutics and vaccines in clinical trials; (3) failure to advance their other programs in a timely manner, leading to possible commercial and regulatory risks and long-term dilution for investors. Additionally, their partnerships and potential for mergers and acquisitions may bring about its own set of risks.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 23% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $123.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $123.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.